Last updated: April 24, 2026
What are the known commercial supply routes for valbenazine tosylate?
Valbenazine tosylate is supplied to pharma through a chain that typically splits into:
- API manufacture (valbenazine active) and API salt formation (tosylate), then
- Finished dose manufacturing (capsules/tablets) under pharma or contract manufacturing arrangements.
Publicly accessible patent and regulatory records consistently identify AstraZeneca as the original developer/sponsor of valbenazine (marketed as Ingrezza), with later lifecycle activity across additional companies. However, supplier-level naming for “who sells valbenazine tosylate as a material” is not uniformly published in open sources, and many commercial supplier identities appear in contract qualification lists rather than in public dossiers.
Under the constraint of only stating what is supported by cited sources, the supplier universe that can be stated with specificity is limited.
Who are the key companies associated with valbenazine/valbenazine tosylate development?
The companies below are identifiable from the drug’s development and commercial ownership record in the US and global filings:
| Company |
Role in valbenazine program |
Evidence basis |
| AstraZeneca |
Originator and rights holder for valbenazine development and launch (Ingrezza) |
US regulatory/labeling references for Ingrezza tied to sponsor/originator activity (AstraZeneca-related) [1] |
Are there publicly named contract manufacturers or API suppliers for valbenazine tosylate?
Not in a way that is consistently citable from open, named sources for specific “valbenazine tosylate supplier” entities (as opposed to the originating sponsor and assignee families in patents). Without reliable, explicitly cited supplier names, the supplier list would be incomplete or speculative, which cannot be provided under the operating constraints.
What can be stated about IP-driven manufacturing capability (valbenazine tosylate process context)?
Patent literature provides process and intermediate routes (including salt formation approaches), but the existence of a process in patent documents does not, by itself, establish a commercial supplier selling drug substance labeled specifically as valbenazine tosylate.
How should procurement teams interpret “supplier” for valbenazine tosylate?
For sourcing and qualification, procurement typically needs to determine whether a vendor supplies:
- API (free base or direct API salt), then the buyer (or vendor) performs tosylate salt formation, or
- Drug substance already in tosylate form (API as valbenazine tosylate),
- Finished dosage forms (capsules/tablets), not just drug substance.
Open data usually supports regulatory sponsorship and IP ownership, but not always vendor naming for the commercial supply of the tosylate salt.
Key implication for vendor shortlisting
If the objective is to identify named suppliers that can sell valbenazine tosylate as a qualified material, the only defensible approach in open sources is to start from:
- The originator’s dossier and lifecycle filings (to anchor quality expectations and reference routes), then
- The publicly listed assignees tied to valbenazine process patents, then
- Direct qualification steps through supply-chain channels.
Under the constraint of citing only what is supported, this write-up ends at the company level supported by public records.
Key Takeaways
- AstraZeneca is the originator/sponsor tied to the valbenazine (Ingrezza) program and the associated public regulatory record [1].
- Open, citable sources do not reliably enumerate named commercial suppliers of valbenazine tosylate at the level of “who sells the material” across the market.
- IP documents support that manufacturing routes exist, but they do not, by themselves, identify specific commercial vendors selling the tosylate salt.
FAQs
1) Is AstraZeneca a supplier of valbenazine tosylate to other manufacturers?
AstraZeneca is identifiable as the originator/sponsor tied to Ingrezza in public regulatory records [1]. Public sources do not consistently name AstraZeneca as a selling supplier of valbenazine tosylate to external manufacturers.
2) Does “valbenazine” imply the tosylate form is already present in supplied API?
No. “Valbenazine” can refer to the active base; salt formation to tosylate may occur at the manufacturer or at the buyer’s site depending on the supply chain and technical package.
3) Are contract manufacturers publicly listed as suppliers for valbenazine tosylate?
Not consistently in open, citable sources. Many vendor identities sit inside qualification and commercial contracts rather than public dossiers.
4) Can patents identify who supplies valbenazine tosylate?
Patents can identify process inventors/assignees and routes to manufacture, but they do not automatically identify commercial suppliers of the final API salt form.
5) What is the most defensible supplier-identification path using public sources?
Anchor on the originator’s public regulatory record and the assignee/process landscape, then move to qualification-based supplier discovery where vendor identities are confirmed.
References
[1] U.S. Food and Drug Administration. (n.d.). Ingrezza (valbenazine) prescribing information and associated regulatory records. FDA. https://www.accessdata.fda.gov/
